Clinical Trial: Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888661) titled 'Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy' on March 03.

Brief Summary: The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of EXG001-307 as a treatment of spinal muscular atrophy .

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Spinal Muscular Atrophy (SMA)

Intervention: BIOLOGICAL: EXG001-307 injection

non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Hangzhou Jiayin Biotech Ltd

Disclaimer: Curated by HT Syndication....